$RNAZ

RedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.

RedChip Companies said it will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on Bloomberg TV Aug 8 and CNBC Aug 9. Virax CEO James Foster discussed its fiscal 2026 annual report, Nasdaq bid compliance, and progress on ViraxImmune and ImmuneSelect, including a Fosun Diagnostics supply deal. Transcode CEO Philippe Calais discussed Phase 2a progress for TTX-MC138 and prior Phase 1a results.

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001829635 0001829635 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

TransCode Therapeutics (NASDAQ: RNAZ) has filed a shelf registration (Form S-3) to allow selling stockholders to resell up to 15.96 million shares of common stock. The company will not receive any proceeds from these sales. The filing details the outstanding shares, conversion mechanics for preferred stock, and outlines various clinical and pipeline developments for its therapeutic candidates, including TTX-MC138 and Seviprotimut-L.

TransCode Therapeutics, Inc. (RNAZ) has delayed the filing of its 2025 Form 10-K, citing complex accounting requirements following several significant transactions on October 8, 2025. These include the acquisition of ABCJ, LLC, a $25 million private placement of Series B preferred stock, and the issuance of contingent value rights (CVRs). The company requires additional time to finalize valuations and accounting for various items like IPR&D, goodwill, and deferred taxes.

TransCode Therapeutics, Inc. has appointed Jack E. Stover to its Board of Directors, where he will also join the Audit and Nominating Committees. Mr. Stover brings over three decades of executive leadership experience in life sciences, including drug development, diagnostics, and capital formation. The company anticipates his expertise will be invaluable as they advance their RNA and immuno-oncology pipelines.

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech unit controlled by the Li Ka-shing family.

TransCode Therapeutics Inc. ( NASDAQ:RNAZ ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.